Sirolimus in renal transplant recipients with malignancies in Germany.

Marcel Ganesh NaikWolfgang ArnsKlemens BuddeFritz DiekmannFrank EitnerWilfried GwinnerNils HeyneJan Steffen JürgensenChristian MorathUdo RiesterKatharina M HellerMichael Fischereder

Published in: Clinical kidney journal (2020)

Conversion to SRL in patients with a history of cancer is safe regarding renal function and graft survival, while patient survival is largely dependent on tumour entity.

Keyphrases

papillary thyroid
free survival
case report
squamous cell
squamous cell carcinoma
young adults
lymph node metastasis